Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...
MedPage Today on MSN
For Your Patients: Next Steps If There Is Resistance to Endocrine Therapy
When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...
Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...
The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...
Triple-negative breast cancer is a fast-moving form of breast cancer that’s more common in younger women and harder to treat ...
Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...
Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...
Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...
MedPage Today on MSN
Endocrine Therapy Resistance in HR+/HER2- Breast Cancer: A Common Clinical Challenge
Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...
Strickland survived a lesser-known, aggressive form of breast cancer, and is now using her second chance on life to be an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback